Skip to main content

Table 4 Clinical factors for renal function decrease

From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Patient

Group D

13 (37.5%)

Group ND

27 (62.5%)

p-value

[background factors]

 Age, median [range]

66 [46–76]

69 [33–78]

0.1650

 Sex, male (%)

2 (15.4)

11 (40.7)

0.0951

 BW (kg), median [range]

57.9 [41.6–74.0]

60.7 [35.3–97.1]

0.4356

 Histopathology, follicular (%)

5 (38.4)

10 (37.0)

0.9306

 Performance status, ≥ 1

6 (46.5%)

11 (40.7%)

0.7460

 eGFR at baseline (mL/min/1.73 m2), median [range]

78.5 [65.2–118.7]

63.8 [43.6–119.1]

0.0165

 eGFR at baseline (mL/min/1.73 m2), < 60

0 (0)

8 (29.6)

0.0072

 Proteinuria grade 1 at baseline, yes (%)

2 (15.4)

0 (0)

0.0298

 Past hypertension history (%)

8 (61.5)

16 (59.3)

0.8903

 Past diabetes mellitus history (%)

1 (7.7)

2 (7.4)

0.9745

 Past renal history (%)

1 (7.7)

5 (18.5)

0.3452

 Renal metastasis, (%)

0 (0)

3 (11.1)

0.1158

 Liver metastasis, (%)

1 (7.7)

6 (22.2)

0.2296

[Treatment-related factors]

 Treatment period (months)

34.1 [12.8–60.5]

25.2 [6.8–61.5]

0.0832

 Observation period (months)

45.4 [21.0–60.5]

27.2 [7.4–61.5]

0.0115

 Dose intensity (mg/day), median [range]

9.7 [4.1–14.0]

9.46 [4.0–16.4]

0.7398

 Best response in RECIST criteria, PR (%)

10 (76.9)

19 (70.4)

0.6606

 Proteinuria grade 3, yes (%)

10 (76.9)

11 (40.7)

0.0283

 Treatment continuation, yes (%)

8 (61.5)

11 (40.7)

0.2161

 Treatment termination due to renal problem, yes (%)

2 (15.4)

5 (18.5)

0.8053